Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

In the initial adjuvant setting,

Michelle has an 89% risk for distant metastases1*

Patients with a high number of positive nodes, like Michelle, are at the greatest risk of recurrence soon after surgery2

Risk of breast cancer recurrence over time2
Chart: Risk of breast cancer recurrence over time

The data reflected in this chart are estimates only and do not take into account individual results.


If Michelle is diagnosed with distant metastases, she would have a 41.3% chance of surviving the next 5 years4

5-year survival by recurrence type4
Chart: 5-year survival by recurrence type

The data reflected in this chart are estimates only and do not take into account individual results.

FEMARA® (letrozole) is the only aromatase inhibitor versus tamoxifen that significantly reduces the risk of distant metastases at 26-month follow-up5,6†‡

At 26-month follow-up, FEMARA® delivered:



At 73-month median follow-up, FEMARA® remains the only aromatase inhibitor versus tamoxifen to7,8:



Click here for more information.

At a median follow-up of 73 months and a median treatment duration of 60 months, the risk of a disease-free survival event was significantly reduced with FEMARA® compared with tamoxifen (intent-to-treat [ITT] analysis: HR 0.87; 95% CI: 0.76-0.99; P=0.03; censored analysis: HR 0.84; 95% CI: 0.73-0.95), confirming the 2005 PCA results.9

Similarly, the updated analysis confirmed the superiority of FEMARA® in reducing the risk of distant metastases (HR 0.85; 95% CI: 0.72-1.00). Additionally, while not statistically significant, overall survival trended toward significance in the ITT analysis.9

Explanation of ITT versus censored analyses

ITT analyses were conducted ignoring the selective crossover. Censored analyses were conducted censoring follow-up/event times at the date of selective crossover in 632 women (26%) who crossed to FEMARA® or another aromatase inhibitor after the tamoxifen arms were unblinded in 2005, based on superior efficacy of FEMARA® over tamoxifen and following the recommendations of the Data Monitoring Committee.9

Of these 632 women, 448 (70%) crossed to FEMARA® to complete initial adjuvant therapy. All of these women were in Option 1 and most crossed in Years 3 to 4, at a median 43 months from randomization. Median duration of FEMARA® after crossing was 17 months. The remaining 184 women crossed to FEMARA® (172 women) or another aromatase inhibitor (12 women) to start extended adjuvant treatment, having received tamoxifen for 4.5 to 5 years.9

Click here for more information.

Your patients at risk of distant metastases need therapy that can help protect them both early and later.1

Start and stay with FEMARA® (letrozole) to help prevent distant metastases.5,7

Return to Case Studies.

To read more about the unique efficacy profile of FEMARA®, click here

*Average risk over 15 years based on prognostic factors of nodal status and tumor size.1
†Distant disease-free survival is a secondary end point of BIG 1-98; the primary end point of the study is disease-free
 survival. Approval is based on a median 26-month follow-up.5
‡Standard adjuvant treatment duration is 5 years or until relapse.5

References: 1. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol. 2000;18(3):591-599. 2. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738-2746. 3. Mansell J, Monypenny IJ, Skene AI, et al. Distant metastasis-the most common type of early recurrence with adjuvant tamoxifen therapy. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas. 4. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. In: Proceedings from the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract 738. 5. FEMARA® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 6. Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106(5):975-981. 7. Mouridsen H, for the BIG 1-98 Collaborative Group. Letrozole monotherapy vs. tamoxifen monotherapy or vs. letrozole in sequence with tamoxifen for postmenopausal women with endocrine-responsive early breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, Texas. 8. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53. 9. Data on file. Novartis Oncology, East Hanover, NJ.